Index

α-glucosidase inhibitors see specific agents

α-lipoic acid (LA) 321

AAI see ankle-arm index

ABCD trial 231, 237–9, 396

ABI see arterial brachial index

absolute risk reduction (ARR)
definition 3
type 2 diabetes 56, 58, 60–1, 74, 82–3

acarbose 70, 77–9, 92, 195, 217, 455–6, 465

ACCORD trial 192–3, 196, 247, 249

ACEI see angiotensin converting enzyme inhibitors

acetyl-L-carnitine (ALC) 321

ACHOIS trial 210–11, 218–19

ACS see acute coronary syndromes

ACT NOW study 77, 92

activation interventions 427–8, 431–2

acupuncture 326

acute coronary syndromes (ACS) 355, 360–1

acute myocardial infarction 365–6

acute painful neuropathy 320

ADDITION study 114–15, 127

adherence 421

adiponectin 262

ADVANCE study 193

advanced glycation end-products (AGEs)
antihypertensive agents 227–8
classification of diabetes 20

erectile dysfunction 344

periodontal disease 306–7

ADVENT trial 245

advertising 481–2

advocacy initiatives 472, 474–6, 479–80

AFCAPS study 241

AFORRD study 245

AGEs see advanced glycation end-products

AIM-HIGH study 245

albumin:creatinine ratio 256

albuminuria

hyperlipidaemia 252

intensive glycaemic management 180, 184

nephropathy 285, 287–9

smoking 164–5

ALC see acetyl-L-carnitine

alcohol 85, 151

aldo reductase inhibitors (ARIs) 320–1

ALERT study 250–1

ALLHAT trial 230, 232, 242–3

alpha-blockers 348

alprostadil 349–50

American Association for Clinical Chemistry 18

American College of Obstetricians and Gynaecologists 51

American Diabetes Association (ADA)
antihypertensive agents 226
classification of diabetes 11–17, 19, 26
cost-effectiveness 455
gestational diabetes mellitus 201, 208

hyperlipidaemia 248–50

lifestyle interventions 150, 152

neuropathy 317

peripheral arterial disease 394, 397

screening 113, 118–19, 127

type 2 diabetes 50, 59

American Heart Association 62, 226

aminoguanidine 228

amlodipine 231–2

amputations see lower extremity amputations

angioplasty 194, 366–7, 399

angiotensin converting enzyme inhibitors

ACEI 80–1

cardiovascular complications 365

cost-effectiveness 456–7, 461, 463–7

hypertension in diabetes 229–35

microalbuminuria 259–60

nephropathy 285–8

peripheral arterial disease 396, 400

angiotensin II receptor blockers (ARBs) 80–1, 229–35, 285–6

anhydroglucitol 122

ankle-arm index (AAI) 405

ankle-brachial index (ABI) 393–4

ante-partum surveillance 211

antibiotics 330–1

anti-CD3 monoclonal antibody 36

anti-CD20 monoclonal antibody 37

anti-CD25 monoclonal antibody 37


© 2010 John Wiley & Sons, Ltd
anticonvulsants 323–4
antihypertensive agents 232–5
active therapies 232–5
advanced glycation end-products 227–8
atherosclerosis 226–7
blood pressure targets 228–30
cardiovascular complications 365
cardiovascular disease 226–40
clinical trials 228–30, 237–40
cost-effectiveness 462
erectile dysfunction 344
macrovascular disease 228
placebo-controlled trials 228–30
prevention of complications 268
retinopathy 276
see also specific agents
anti-obesity agents see orlistat
antioxidants 83–4, 151–2
antiplatelet therapy 363–4, 381, 397–8
apolipoprotein A1 161
ARIC study 151, 261–2, 360, 365
ARIs see aldose reductase inhibitors
ARR see absolute risk reduction
autonomic dysfunction 32, 33
autonomic neuropathy 326–33, 361
azathioprine 34–5

β-carotene 83–4, 151
β-cells classification of diabetes 11–12, 25, 27
type 1 diabetes 31–41
type 2 diabetes 62
B-lymphocytes 37
bacterial Calmette–Guerin (BCG) vaccine 35
BARI study 194, 366–7
bariatric surgery 85, 144
BCG see bacterial Calmette–Guerin
Behavioral Risk Factor Surveillance System (BRFSS) 162, 172
BENEDICT study 286–7
Best Evidence 50
beta-blockers cardiovascular complications 364–5
cost-effectiveness 457
hypertension in diabetes 231–5
neuropathy 328–9
peripheral arterial disease 396
bezafibrate 72–3, 246
Bienestar Health Program 90
BIF study 246
BIGPRO trial 69, 73–4
biguanides see metformin bile acid resins 244
capillary glucose tests 120
capillary blood glucose 18
capillary glucose tests 120
coronary artery disease 360–1
coronary revascularization 366–8
hyperglycaemia 365–6
hypertension 358, 365
lipid-lowering therapies 365
management 363–8
reperfusion therapy 365
risk factors 355–60, 362
type 2 diabetes 77, 78
weight change 366
coronary artery disease 360–1, 362–3
correction revascularization 366–8
detection 362–3
heart failure 355, 361–2
heart muscle metabolism 360
hyperglycaemia 365–6
hypertension 358, 365
lipid-lowering therapies 365
management 363–8
reperfusion therapy 366
risk factors 355–60, 362
type 2 diabetes 77, 78
weight change 366
cardiovascular autonomic neuropathy (CAN) 326–33
cardiovascular complications 355–76
ACE inhibitors 365
acute coronary syndromes 360–1
antiplatelet agents 363–4
assessment 362
autonomic neuropathy 361
beta-blockers 364–5
cardiomyopathy 361
clotting-related abnormalities 359–60
coronary artery disease 360–1, 362–3
correction revascularization 366–8
detection 362–3
heart failure 355, 361–2
heart muscle metabolism 360
hyperglycaemia 365–6
hypertension 358, 365
lipid-lowering therapies 365
management 363–8
reperfusion therapy 366
risk factors 355–60, 362
type 2 diabetes 77, 78
weight change 366
hyperglycaemia management 268
hyperlipidaemia 241–52
Index
Index

intensive glycaemic management 182–4, 190–6
lifestyle interventions 145–6, 148
nephropathy 287
primordial prevention 90–1
risk factors 269, 355, 357–60, 368
screening 115
smoking 161, 163, 168, 173
surgical interventions 145
therapeutic targets 269
type 1 diabetes 257–9
type 2 diabetes 78, 256–9
see also microalbuminuria
CARDS trial 242–3, 248
CARE study 241–3, 252
carotid endarterectomy (CEA) 383–4
carotid plaque inflammation 355
CATS study 382
CCF see congestive cardiac failure
CDC see Centers for Disease Control and Prevention
CDPP see Community Diabetes Prevention Project
CEA see carotid endarterectomy
Centers for Disease Control and Prevention (CDC) 449, 455
central obesity 14
CER see control event rate; cost-effectiveness ratio
cerebrovascular disease 377–92
classification of diabetes 9
epidemiology 377–9
haemorrhagic stroke 378–9
hyperglycaemia 378–81, 384–6
ischaemic stroke 377–8, 384
pathophysiology 379
preventative measures 380–4
stroke outcomes 379–80
surgical interventions 383–4
thrombolytic therapy 386–7
treatment 380–7
CHARISMA trial 364
CHARM study 71, 81
CHD see coronary heart disease
childhood diabetes 33
chloropropamide 191, 214–16
chlorothalidone 71
Cholesterol Treatment Trialists Collaboration (CTTC) 243, 250
chromium supplementation 83, 152
chronic kidney disease 250–1, 256
cilostazol 399, 400
CINAHL 440, 443, 450–1
cisapride 329
CLAS study 397
classification of diabetes 9–24
bimodal glucose distribution 14–15, 21
commentary 25–8
current criteria 14
diagnostic criteria 10
diagnostic test comparison 17–20
evidence base for diagnostic thresholds 14–17
historical development 9–14
insulin sensitivity-based 9–12
long-term complications 15
non-invasive diagnostic tests 20
nonlinearity of risk 25–6
recent changes 10–14
risk categories 13–14
staging 26, 28
claudication 394, 398–9
clavicular fracture 205
clinical onset 32
Clinical Trials Registry 50
clopidogrel 364, 382, 398
clopidogrel 364, 382, 398
clothing-related abnormalities 359–60
CMAPs see compound muscle action potentials
CMP see cow milk proteins
Cochrane Collaboration 4–5
cost-effectiveness 450–1
intensive glycaemic management 193–4
lifestyle interventions 151
self-management 425
type 2 diabetes 50
combination tests 121–2, 126
combined lifestyle interventions 52–64
communication continuum 426–30
Community Diabetes Prevention Project (CDPP) 54, 58
community mobilization 472–3, 474–6, 479–80
compliance 421
compound muscle action potentials (CMAPs) 320
congenital malformations 215
congestive cardiac failure (CCF) 355, 361–2
constipation 327
continuous subcutaneous insulin infusion (CSI) 186
cost-effectiveness ratio (CER) 450–63
Cow milk proteins (CMP) 40–1
Cox-2 enzyme 227–8
cranial neuropathy 332
CRESSENDO study 196, 366
CREST study 384
CRP see C-reactive protein
CSII see continuous subcutaneous insulin infusion
CT (conventional therapy) see insulin therapy
CTCP see California Tobacco Control Program
CTTC see Cholesterol Treatment Trialists Collaboration
CVD see cardiovascular disease
D-Net see Diabetes Network
daclizumab (DZB) 37
dacarbazine 481
Index

DAFNE project 422
DAISI study 92
DALYs see disability-adjusted life years
DaQing IGT and Diabetes Study (China) 53, 56–7, 63–4
Data Safety and Monitoring Board (DSMB) 37
DCCT trial
cardiac complications 365
cerebrovascular disease 381
cost-effectiveness 454–5, 461, 463, 467
foot ulcers 405
intensive glycaemic management 180, 183–6
neuropathy 317–18
peripheral arterial disease 395
delivering diabetes care 438–48
developing countries 445–7
general practice/hospital care 439, 441–3
literature review 440–4
primary care 439
public policy 473
socio-economic factors 445–6
type 1 diabetes 443, 445

type 2 diabetes 439, 443, 446
DENIS study 38
DETAIL trial 286–7
detmir 212–14
DHA see docosahexaenoic acid
Diabetes Care Asia 445
Diabetes Network (D-Net) 424
Diabetes Prevention Program (DPP) cost-effectiveness 451–2
type 2 diabetes 55, 59, 62–7, 69, 74, 76
DIABETES study 367–8
diabetic amyotrophy 332–3
diabetic ketoacidosis (DKA) 9, 185, 359
DIABHYCAR trial 230–1, 258
diarrhoea 330–1
diet
composition 65–7
energy restriction 140–1
gestational diabetes mellitus 86–8
glycaemic index/glycaemic load 142, 150–1
long-term outcome trials 153–4
low-carbohydrate diets 141–2
nutritional effects 149–53
public policy 475–6, 477–8, 481–2
risk factors 51–2
self-management 424
supplementation 83–5
type 1 diabetes 151, 153
weight change 140–3
DIGAMI study 193, 365–6
dihydroergotamine 328
diltiazem 231
dipeptidylpeptidase-4 (DPP-4) 79, 144
DIPP study 40
dipyridamole 382–3
disability-adjusted life years (DALYs) 446
distal symmetric sensorimotor polyneuropathy 319
diabetes 80
DKA see diabetic ketoacidosis
docosahexaenoic acid (DHA) 245
domeridone 329
DPP see Diabetes Prevention Program
DPP-4 see dipeptidylpeptidase-4
DPS study 54, 58–9, 62–7
DPT-1 trial 33, 39, 41
DPV see Germany diabetes documentation and quality management system
DREAM study 70, 72, 77, 80–1, 230–1, 233
DRVS study 281
DSMB see Data Safety and Monitoring Board
duloxetine hydrochloride 323
duodenal switch 144
dysglycaemia 32, 33
dyslipidaemia
classification of diabetes 14, 27
delivering diabetes care 446
medical treatments 241
microalbuminuria 259
DZB see daclizumab
EASD 26
ECASS study 387
ECG see electrocardiography
Economist Intelligence Unit 438
ECST trial 383–4
EDIC study 166, 183, 275, 318, 365, 381, 395
EDIT trial 78–9
EER see experimental event rate
effective communication pathways 430–3
Effective Healthcare Bulletins 4
Effective Practice and Organization of Care (EPOC) 443
Eicosapentaenoic acid (EPA) 245
electrocardiography (ECG) 361, 363
electrodiagnostic studies 320
EMBASE 440, 443, 450–1
emotional support 423–4, 427
empowerment interventions 428–32
enalapril 71, 286–7
end-stage renal disease (ESRD) 285–7
cost-effectiveness 456, 457, 461–2, 465
periodontal disease 308–9
screening 112, 114, 116
ENDIT trial 38, 41
endothelial dysfunction 259
energy restriction 140–1
environmental factors 472, 476–7, 480, 482
EPA see eicosapentaenoic acid
epidemiological studies
delivering diabetes care 439, 444
gestational diabetes mellitus 88
lifestyle interventions 148, 149
neuropathy 318
periodontal disease 292–3, 305–8
type 2 diabetes 66–7
EPOC see Effective Practice and Organization of Care
Epstein–Barr virus 36
erectile dysfunction 341–54
assessment 345
classification of diabetes 9
clinical features 345
insulin resistance 344
management 345–6
metabolic syndrome 344
neuropathy 327, 331, 348
non-systemic treatments 349–50
normal penile erection 342–3
pathophysiology 342–4
prevalence 341–2
quality of life 345
risk factors 341
testosterone 344
treatment 346–50
type 2 diabetes 344
erythromycin 329–30
erthropoietin 328
ESPRIT study 383
ESPIS study 382–3
ESRD see end-stage renal disease
ETDRS study 191, 251, 276, 278–80, 397
ethnicity
cardiovascular complications 355
cardiovascular disease 257
gestational diabetes mellitus 199
intensive glycaemic management 191
microalbuminuria 257
EURODIAB study 164–6, 168, 170, 251, 261, 317–18
EUROPA trial 229–31
EVA-3S study 384
fibrillar 360
fibrocalculous pancreatic diabetes
(FCPD) 12–13
FIELD study 246, 252, 365
first-phase insulin response
(FPIR) 32, 33, 38
fish oil supplementation 149–50
fludrocortisone acetate 328
fluorescein angiography of the
fundus 278
fluoxetine 144
folic acid 262
food subsidies 481
foot ulcers 403–17
cost-effectiveness 460–1
evidence-based research 407–15
examinations 407, 409–11
exercise 407, 411
long-term outcome trials 206–12
foot ulcers 412–13
self-management 407, 409
systems of care 413–15
therapeutic footwear 411–12
forskolin 231
FOX5 37
FPD see fasting plasma glucose
FPIR see first-phase insulin response
Framework Convention on Tobacco
Control (FCTC) 482, 483
Framingham Heart Study 377, 394
frequently sampled intravenous
glucose tolerance test (FSIGT) 77
fructosamine 119–21, 151
GFR see glomerular filtration rate
GFR see glucose–potassium–insulin
GIR see glycemic index
GKT see glucose–potassium–insulin
Glar 194–5, 212–14
Glibenclamide 191
Gliclazide 53, 57
glibizide 214
Glucomer filtration rate (GFR) 148,
151, 285–9
Glucagon-like peptide-1 (GLP-1) 79, 144
glucose challenge tests (GCT) 13
glucose intolerance 378

Index
Index

glucose–potassium–insulin (GKI) infusion 193, 385–6
glutamic acid decarboxylase (GAD) 33, 36–7
glutathione (GSH) 321
glyburide 214–16, 456
glycaemic index (GI) 142, 150–1
glycaemic management see insulin therapy; intensive glycaemic management
lifestyle interventions (Continued) 430
self-management 430
  type 2 diabetes 52–67, 83–5, 91–4, 266–7
  smoking; weight change 430
lifestyle modification (LSM) 55, 59–60
limb mononeuropathy 332
linomide 35
LIPID study 72, 82, 241–3, 252
lipid-lowering agents see specific agents 141–2
lipopolysaccharides (LPS) 306–7
lobbying 472
LODZ study 92
Look AHEAD trial 138–9, 194, 366
losartan 233, 461–2
lovastatin 397
low density lipoprotein (LDL) cholesterol 147–8, 150
antihypertensive agents 226–7
cardiovascular complications 358, 362, 365
cost-effectiveness 457–8
erectile dysfunction 344
hyperlipidaemia 241–4, 246–52
lifestyle interventions 147–8, 150
microalbuminuria 256
periodontal disease 307
peripheral arterial disease 396–7, 400
prevention of complications 269
smoking 161
type 2 diabetes 57, 74–5, 81
low-carbohydrate diets 141–2, 151
lower extremity amputations (LEA) 403
cost-effectiveness 460–1
peripheral arterial disease 393–4
preventive measures 407–15
risk factors 407–8
screening 112, 114, 116
LPS see lipopolysaccharides 139
LRC-CPPT trial 244
LSM see lifestyle modification 430
LTPA see leisure-time physical activity 85
LYGs see life-years gained 326
macrolibunuria 286, 309
macrosomia 205–6, 208, 212
macrovacular disease 228
macular oedema 280–1
maculopathy 276–8
magnesium supplementation 84, 152
major histocompatibility complex (MHC) 31, 32–3
malnutrition-related diabetes mellitus (MRDM) 10, 12
MATCH study 382
MDRD see Modified Diet in Renal Disease 430
Medicaid 449
medical nutritional therapy 207
Medicare 449
medicated urethral system for erection (MUSE) 370
MEDLINE 50, 440, 443, 450–1
meglitinide 214
Melbourne study (Australia) 54, 58
metabolic memory 184
metabolic syndrome 344
metformin
  cardiovascular complications 366
cost-effectiveness 452, 455–6
gestational diabetes mellitus 214–17, 219
  intensive glycaemic management 191–2, 195
  type 2 diabetes 55, 59–60, 68–9, 73–5, 92
  weight change 144
methylodopa 70
metoclopramide 329
mexiletine 325
MHC see major histocompatibility complex
MI see myocardial infarction 430
MICRO-HOPE study 229, 259, 286
microalbuminuria 164–5, 256–60
cardiovascular complications 369
cost-effectiveness 461–2, 466–7
ethnicity 257
inflammatory markers 261
intensive glycaemic management 180, 184
nephropathy 285–8
retinopathy 276
risk factors 258–9
  treatment 250
  type 1 diabetes 257–9
  type 2 diabetes 256–9
Microalbuminuria Collaborative Study Group 165, 180
microvascular complications 178–81, 251–2
MIG study 216
miglitol 77
milk proteins 40–1
MMF see mycophenolate mofetil
Modified Diet in Renal Disease (MDRD) formula 362
MODY type diabetes 27
monounsaturated fatty acids (MUFA) 149
MOS study 429
MRDM see malnutrition-related diabetes mellitus 430
MRFIT trial 55, 60–1, 168–9, 171
MUFA see monounsaturated fatty acids 430
multi-component interventions 462–3
Multi-ethnic study of Atherosclerosis 162
Multifactorial Primary Prevention Trial 169, 171
MUSE see medicated urethral system for erection 370
mycophenolate mofetil (MMF) 37
myocardial infarction (MI)
  antihypertensive agents 228–9, 232, 235
cardiovascular complications 355, 360–1, 363, 365–6, 368
  intensive glycaemic management 191–2, 194–6
  peripheral arterial disease 393, 397–8
myocardial ischaemia 195
NAION see non-arteritic anterior ischaemic optic neuropathy 39–40
NASCET trial 383–4
nateglinide 91–2, 194
National Cholesterol Education Program (NCEP) 142, 245, 247–9
National Diabetes Data Group (NDDG) 10–11, 13, 112
National Heart Forum 481
National Institute for Health and Clinical Excellence (NICE) 196, 449
National Institute of Neurological Disorders and Stroke (NINDS) 386–7
National Kidney Foundation (KDOQI) 251
National Programme for Prevention and Control of Diabetes 447
National Service Framework 473
Natural History of Microalbuminuria Study 165
NAVIGATOR study 194
Navigator Trial 91
NCDs see non-communicable diseases 285–90
albuminuria 285, 287–9
blood pressure lowering 285–90
cardiovascular complications 358
classification of diabetes 9, 15–16, 19

cost-effectiveness 461–2

intensive glycaemic management 179–81, 184, 193

meta-analyses of blood pressure lowering 285–7

microalbuminuria 285–8

retinopathy 276

smoking 164

neuropathy 317–40

asymmetric lower limb motor neuropathy 332–3

autonomic 326–33, 361

bladder dysfunction 327, 331

classification 317–18

cost-effectiveness 460–1

cranial 332

diagnostic criteria 317–18

diarrhoea 330–1

distal symmetric sensorimotor polyneuropathy 319

electrodiagnostic studies 320

erectile dysfunction 337, 348

foot ulcers 405, 407, 411

gastroparesis 327, 329–30

hyperlipidaemia 252

intensive glycaemic management 178–81

limb mononeuropathy 332

microalbuminuria 258

non-systemic treatments 326, 327

pain control 322–6

pathogenesis 317–18

prevalence 317–18

screening 319

small-fibre sensory neuropathy 321–2

smoking 164

treatment 320–6, 327–31

truncal mononeuropathy 332

neutral protamine Hagedorn (NPH) insulin 194, 210

Newcastle-upon-Tyne study (UK) 56, 61

NGF see nerve growth factor

NHANES studies 404

periodontal disease 292

screening 119

smoking 169, 171

type 2 diabetes 65

NHDS study 404–5, 407

niacin 245–6

NICE see National Institute for Health and Clinical Excellence

nicorandil 348

nicotinamide 35, 37–8, 41

nicotinic acid 245–6

NIDDM see non-insulin-dependent diabetes mellitus

NINDS see National Institute of Neurological Disorders and Stroke

nisoldipine 231

nitrate therapy 348

nintrendipine 229

nitrous oxide 343–4, 346

NNT see number needed to treat

cost-effectiveness 453–4


screening 113

type 1 diabetes 39

oral insulin 36, 41

ORIGIN study 194–5

orlistat 70, 79–80, 143

orthostatic hypotension 327

PAD see peripheral arterial disease

PAI-1 see plasminogen activator inhibitor

PAM study 366

pan-retinal photocoagulation (PRP) 279–80

papaverine 349–50

participation interventions 426–7

patient preferences 439

patient-practitioner relationship 425, 427, 429–30

PCI-CURE study 364

PCOS see polycystic ovary syndrome

PDDM see protein-deficient pancreatic diabetes

PDE-5 see phosphodiesterase type 5

PFD see protein-deficient pancreatic diabetes

PDS see Prospective Diabetes Study

PEACE study 71, 80–1

pegaptanib 281

pentoxifylline 399

correlation 281

percutaneous transluminal coronary angioplasty (PTCA) 366–7

perinatal mortality/morbidity 201, 205, 270

perindopril 229–31, 287

periodontal disease 291–316

cellular and molecular dynamics 300, 306–7

gestational diabetes mellitus 292, 296–7, 300

glycaemic management 292–305, 307–9

literature review 292–305

type 1 diabetes 292–304, 307

type 2 diabetes 292–305

periodontitis 291

Peripheral arterial disease

(PAD) 355, 393–402

anti-platelet therapy 397–8

cladication 394, 398–9

epidemiology 393–4

exercise 398–9, 400

foot ulcers 394, 407

risk factors 394–7, 400
Index

peripheral arterial disease (Continued)
surgical interventions 393–4, 399
type 2 diabetes 393–402
peripheral neuropathy 405, 407, 411
peripheral vascular disease 9
phenformin 190
phosphodiesterase type 5 (PDE-5) inhibitors 331, 346–9
photoocoagulation 276–80
physical activity see exercise
Physicians’ Health Study 398
Pima Indians 14–16, 292, 308
pimagedine 228
pioglitazone 69–70, 75–7, 92–4, 195, 366, 455–6, 466
PIPOD study 76
pitavastatin 92–3
Pittsburg study (USA) 54, 57–8
Pittsburgh Epidemiology of Diabetes Complications Study 170
PKC see protein kinase C
placebo-controlled trials 228–30
plasminogen activator inhibitor (PAI-1) 59
platelet aggregation 359–60
polycystic ovary syndrome (PCOS) 214–17
polycythaemia 205
polyunsaturated fatty acids (PUFA) 149–50
polyuria 9
population-based strategies 94–5
delivering diabetes care 444
foot ulcers 415
screening 123, 125–6
POSH study 397
positive predictive value (PPV) 117–18
post-term diabetes 217–18
PPP trial 397–8
PPV see positive predictive value
PRoFESS study 383
pravastatin 72, 82, 242–4, 268–9
pre-eclampsia 202
prediabetes 26
pregabalin 324
pregnancy see gestational diabetes mellitus
prevention of diabetes
animal studies 67
bariatric surgery 85
cost-effectiveness 62–3, 67
definition 3
developmental stages 31–2
gestational diabetes mellitus 50–1, 57–8, 75–6, 85–9, 95
high risk type 1 individuals 37–41
human studies 67–8
interruption of disease process 33–4
lifestyle interventions 52–67, 83–5, 91–4
natural history and risk factors 51–2
newly diagnosed type 1 diabetes 34–7
pharmacological interventions 68–85, 91–4
primordial 89–91
prospective epidemiological studies 66–7
rational and requirements 49–50
risk identification 32–3
strategies 94–5
type 1 diabetes 31–48
type 2 diabetes 49–85, 91–4
weight change 67–8
see also screening
priapism 350
primary care delivery 439
primordial prevention 89–91
PROactive study 192, 366
proliferative retinopathy 180, 184, 213
Prospective Diabetes Study (UKPDS) antihypertensive agents 228, 237–9
cardiovascular complications 365–6
cerebrovascular disease 380
cost-effectiveness 455–6, 463
glycaemic management 268
intensive glycaemic management 191–2
lifestyle interventions 139
neuropathy 318
periodontal disease 308
peripheral arterial disease 394–6
retinopathy 275
screening 115–17
smoking 166–7
PROSPER trial 242–3
protein (dietary) 142, 151
protein kinase C (PKC) 194, 318
protein-deficient pancreatic diabetes (PDPD) 12
proteinuria 276, 461–2
Projecto VER 162
PRP see pan-retinal photocoagulation
PsychINFO 450–1
psychological interventions 326
PTCA see percutaneous transluminal coronary angioplasty
public policy 471–88
advocacy initiatives 472, 474–6, 479–80
built environment 472, 476–7, 480, 482
community mobilization 472–3, 474–6, 479–80
effectiveness of public health interventions 479–82, 484
global perspective 482–3
legislation and regulation 472, 477–8, 480–2
literature review 473–9
policy levers 472–3, 474–8
policy-making process 471–2
smoking 482, 483–4
type 2 diabetes 473, 482, 484
voluntary agreements 477–8, 481
PUFA see polyunsaturated fatty acids
pyradoxamine 228
QALYs see quality-adjusted life years
QoL see quality of life
QRST study 397
QST see quantitative sensory testing
quality of life (QoL) 345
neuropathy 319
screening 117, 122, 127
Quality and Outcomes Framework 439
quality-adjusted life years (QALYs) 63
cost-effectiveness 450–6, 458–62, 465, 467
screening 112–14, 116, 125
quantitative sensory testing (QST) 320, 322
RAGE see receptor for AGEs
ramipril 71–2, 230–1, 258, 268
Rancho Bernardo Study 169
random blood glucose 17–18
random plasma glucose (RPG) screening 453
randomized, controlled trials (RCTs) 1–2
delivering diabetes care 443–4
gestational diabetes mellitus 206–12, 219
lifestyle interventions 138, 140, 148, 151–2
periodontal disease 308
public policy 473–4
results presentation 5
screening 114–17, 128
type 1 diabetes 40
type 2 diabetes 49–50, 52–66, 68–85, 91–4
ranirestat 321
RAPSODI study 93–4
RCTs see randomized, controlled trials
receiver operating characteristic (ROC) curves 16, 118, 119
receptor for AGEs (RAGE) 227–8, 306–7
RECORD study 195
regulatory levers 472, 480–2
relative risk reduction (RRR) 3
relative risk (RR)
gestational diabetes mellitus 86–8
smoking 166
type 2 diabetes 57, 64
RENAAL study 286–8, 461–2
renal disease 276
renal plasma flow (RPF) 148
reperfusion therapy 366
retinopathy 275–84
antihypertensive agents 276
classification 276–8
classification of diabetes 9, 15–16, 19
cost-effectiveness 458–60, 466
fluorescein angiography of the fundus 278
foot ulcers 407
gestational diabetes mellitus 213, 276
glycaemic management 267, 275–6
hyperlipidaemia 252
intensive glycaemic management 179–81, 184, 190–1
macular oedema 280–1
optical coherence tomography 279
pan-retinal photocoagulation 279–80
proliferative 180, 184, 213
proteinuria 276
risk factors 275–6
screening 276–8
smoking 164–8
treatment 279–81
visual acuity 278, 281
vitrectomy 281
rimonabant 93, 143, 195, 366
RIO-Europe trial 143–4, 366
risk equations 121
risk scores 121
rituximab 37
ROC see receiver operating characteristic
Rochester Diabetic Neuropathy Study 166, 317
rosiglitazone 70, 75–7, 92, 195, 217, 230–1
rosuvastatin 244, 251
RPF see renal plasma flow
RPG see random plasma glucose
RR see relative risk
RRR see relative risk reduction
San Luis Valley Diabetes Study 166–7
Sandy Lake Diabetes Complications Study 163
SAPPHIRE study 384
Schwabing Insulin Prophylaxis Trial 38
SCOPE study 71, 81
Scottish Intercollegiate Guidelines Network (SIGN) 196
SCOUT study 195–6, 366
screening
evaluating benefits of early detection 113–15
biases 115, 118
biochemical tests 119–22
characteristics of tests 117–18, 120–1
combination tests 121–2, 126
continuous/ongoing 126
cost-effectiveness 112, 122–6, 452–4, 458–60, 466
detection and treatment of complications 116
diagnosable preclinical states 113
diagnostic criteria 114
gestational diabetes mellitus 50–1, 203–5, 211, 219
glycaemic control 115–16
historical development 111–12
methodology of evaluations 118
natural history of diabetes 112–13
neuropathy 319
performance 118–22
potential benefits 115–16
principles 112–26
quality of life parameters 112–17, 122, 125, 127
questionnaires 118–19
recommendations and policies 125, 127
reliability and risk assessment 117–22
retinopathy 276–8
risks of early detection 116–17, 122
strategies 123–6
type 2 diabetes 111–34
SDIS study 165–7, 179, 182, 184–6
selective serotonin reuptake inhibitors (SSRIs) 323
self-management 421–37
activation interventions 427–8, 431–2
clinical practice 433–4
communication continuum 426–30
cost-effectiveness 435
decision specificity 424–5
definitions and background 421–2
effect sizes 422–3
effective communication pathways 430–3
empowerment interventions 428–32
foot ulcers 407, 409
framework 426
group interventions 423–4
internet peer support 424
literature review 422–3
participation interventions 426–7
patient engagement in communication 425–35
patient-practitioner relationship 425, 427, 429–30
psychological/personality attributes 424
semidevelopmental factors 424
social support 423–4
SEND CAP study 241
sensory nerve action potentials (SNAPs) 320
sertraline 144
sexual dysfunction see erectile dysfunction
SFNS see small-fibre sensory neuropathy
SGA see small for gestational age
SHARP trial 244, 251
SHEP study 71, 80
sialic acid 260–1
sibutramine 79–80, 143
SIGN see Scottish Intercollegiate Guidelines Network
sildenafil 347–9
simvastatin 72, 241–4, 249, 268–9, 396–7, 457, 467
SIRIUS study 367–8
SIRTAX study 367–8
SLIM study 61
small for gestational age (SGA) birth weights 208
small-fibre sensory neuropathy (SFSN) 321–2
SMART study 257
smoking
all-cause mortality 168–72
cardiovascular complications 356, 358
clinical trials 161, 172
diabetic complications 164–72
foot ulcers 405
interference mechanisms 161–2
microalbuminuria 259
peripheral arterial disease 395, 400
prevalence 162–4
smoking (Continued)
prevention of complications 161–77, 267
public policy 482, 483–4
recommendations 173
risk factors 51, 85, 91
type 1 diabetes 161, 164–6
type 2 diabetes 55, 60–1, 64, 161, 164, 166
SNAPs see sensory nerve action potentials
Soc Abs database 450–1
social support 423–4
SOLVD study 71, 80
somatostatins 329
Sorbinil Retinopathy Trial 166–7
somatostatins 329
SOLVD study 71, 80
social support 423–4
Soc Abs database 450–1
T-helper cells 36
T-cells 39
tadalafil 347–9
Taiwan Lifestyle Trial 92
Task Force on Community Preventive Services 89–90
TASS study 382
TAXUS-IV study 367–8
TCAs see tricyclic antidepressants
TcPO2 see transcutaneous oxygen tension
television advertising 481–2
telmisartan 92, 230, 268, 286–7
TENS see transcutaneous electrical nerve stimulation
testosterone 344
TGF-β see transforming growth factor
therapeutic footwear 411–12
thiazolidinediones (TZDs) 366
see also specific agents
thirst 9
THIS trial 386
thrombolytic therapy 386–7
TIA see transient ischaemic attack
ticlopidine 381–2
TNF-α see tumour necrosis factor
tobacco see smoking
tocopherols 152
Tokyo study (Japan) 55, 60
tolbutamide 68, 190, 216
topiramate 144
total diabetes 32
trandolapril 71, 230, 232, 287
TRANSCEND study 92–3, 230–2
transcutaneous electrical nerve stimulation (TENS) 326
transcutaneous oxygen tension (TcPO2) 405
transforming growth factor (TGF-β) 37
transient ischaemic attack
(TIA) 377–8, 380
transurethral alprostadil 350
TRIPOD study 76, 218
TRITON-TIMI 38 study 364
troglitazone 69–70, 75–6, 218
tropicamide 278
truncal mononeuropathy 332
tumour necrosis factor (TNF-α) 89, 306–7
Type 1 Diabetes TrialNet 37, 39
TZDs see specific agents;
thiazolidinediones
UAS see unstable angina
UGDP see University Group Diabetes Program
UKPDS see Prospective Diabetes Study
unclassifiable retinopathy 276–8
United States Preventive Services Task Force (USPSTF) 2–3, 127
University Group Diabetes Program (UGDP) 190
unstable angina (UAS) 355
Uppsala study (Sweden) 53, 56
urine glucose tests 17, 120
USPSTF see United States Preventive Services Task Force
VA-HIT study 241, 246, 249, 394
vacuum therapy 349
VADT trial 190
valsartan 91–2, 194
vardenafil 347–9
vaso-active intestinal polypeptide (VIP) 350
venous blood glucose 15, 18
venous glucose tests 120
verapamil 230, 232, 287
Verona Diabetes Study 163
very low density lipoprotein (VLDL) cholesterol 149, 161
Veterans Affairs Cooperative Study 190
VIP see vaso-active intestinal polypeptide
visual acuity 278, 281
vitamin C 83–4, 88, 151–2
vitamin D 84–5, 151–2
vitamin E 151–2, 397–8
vitrectomy 281
VLDL see very low density lipoprotein
VO2max 57, 146, 148
voglibose 77
voluntary agreements 477–8, 481
warfarin 383
WASID study 383
WDF see World Diabetes Foundation
Web of Science 450–1
weight change approaches 139–40
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>cardiovascular complications</td>
</tr>
<tr>
<td>classification of diabetes</td>
</tr>
<tr>
<td>cost-effectiveness</td>
</tr>
<tr>
<td>diet</td>
</tr>
<tr>
<td>effectiveness</td>
</tr>
<tr>
<td>energy restriction</td>
</tr>
<tr>
<td>exercise</td>
</tr>
<tr>
<td>glycaemic control</td>
</tr>
<tr>
<td>glycaemic index/glycaemic load</td>
</tr>
<tr>
<td>intensive glycaemic management</td>
</tr>
<tr>
<td>non-responders</td>
</tr>
<tr>
<td>pharmacological interventions</td>
</tr>
<tr>
<td>prevention of complications</td>
</tr>
<tr>
<td>public policy</td>
</tr>
<tr>
<td>risk factors</td>
</tr>
<tr>
<td>self-management</td>
</tr>
<tr>
<td>surgical interventions</td>
</tr>
<tr>
<td>type 2 diabetes</td>
</tr>
<tr>
<td>WHI study</td>
</tr>
<tr>
<td>Whitehall study (UK)</td>
</tr>
<tr>
<td>WHO see World Health Organization</td>
</tr>
<tr>
<td>willingness to pay (WTP)</td>
</tr>
<tr>
<td>Wisconsin Epidemiology Study of Diabetic Retinopathy</td>
</tr>
<tr>
<td>Women’s Health Study</td>
</tr>
<tr>
<td>Women’s Healthy Lifestyle Project</td>
</tr>
<tr>
<td>World Diabetes Foundation (WDF)</td>
</tr>
<tr>
<td>World Health Organization (WHO)</td>
</tr>
<tr>
<td>delivering diabetes care</td>
</tr>
<tr>
<td>gestational diabetes</td>
</tr>
<tr>
<td>lifestyle interventions</td>
</tr>
<tr>
<td>public policy</td>
</tr>
<tr>
<td>screening</td>
</tr>
<tr>
<td>smoking</td>
</tr>
<tr>
<td>type 2 diabetes</td>
</tr>
<tr>
<td>WOSCOPS study</td>
</tr>
<tr>
<td>WTP see willingness to pay</td>
</tr>
<tr>
<td>zenarestat</td>
</tr>
<tr>
<td>zinc supplementation</td>
</tr>
<tr>
<td>zonisamide</td>
</tr>
</tbody>
</table>

This index was prepared by Neil Manley.